PepGen, Inc. (NASDAQ:PEPG) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• PepGen, Inc. has received a consensus rating of "Moderate Buy" from analysts, with one sell rating and four buy ratings among the five brokerages covering the firm.
• The average 12-month target price for PepGen's stock is $8.40, with recent price targets set by various analysts ranging from $6.00 to $12.00.
• After their latest earnings report, PepGen exceeded analysts' expectations by reporting an EPS of ($0.70), compared to the consensus estimate of ($0.85).

PepGen, Inc. (NASDAQ:PEPG - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $8.40.

PEPG has been the topic of a number of research reports. Guggenheim reiterated a "buy" rating and issued a $6.00 price objective on shares of PepGen in a research note on Wednesday. HC Wainwright increased their price target on shares of PepGen from $8.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday. Stifel Nicolaus increased their price target on shares of PepGen from $9.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Wedbush increased their price target on shares of PepGen from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Thursday.

Institutional Trading of PepGen

A number of hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its position in shares of PepGen by 68.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,350,000 shares of the company's stock valued at $1,897,000 after purchasing an additional 550,000 shares during the period. Woodline Partners LP acquired a new stake in shares of PepGen in the first quarter valued at about $1,097,000. Northern Trust Corp grew its position in shares of PepGen by 5.4% in the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company's stock valued at $595,000 after purchasing an additional 7,984 shares during the period. Millennium Management LLC grew its position in shares of PepGen by 1,033.2% in the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company's stock valued at $594,000 after purchasing an additional 142,814 shares during the period. Finally, RBF Capital LLC acquired a new stake in shares of PepGen in the second quarter valued at about $111,000. 58.01% of the stock is owned by hedge funds and other institutional investors.

PepGen Stock Performance

NASDAQ:PEPG traded up $3.17 during midday trading on Thursday, reaching $5.83. 122,220,898 shares of the stock traded hands, compared to its average volume of 2,010,095. PepGen has a 12-month low of $0.88 and a 12-month high of $9.94. The business has a 50-day moving average of $1.42 and a two-hundred day moving average of $1.45. The stock has a market capitalization of $191.06 million, a PE ratio of -1.97 and a beta of 1.17.

PepGen (NASDAQ:PEPG - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.15. Research analysts anticipate that PepGen will post -2.73 earnings per share for the current year.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.